Microarray profiling reveals the integrated stress response is activated by halofuginone in mammary epithelial cells

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Kamberov, Yana G ^a   Kim, Jihoon ^b   Mazitschek, Ralph ^c   Kuo, Winston P ^a,d,e   Whitman, Malcolm ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053501725     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-381     Document Type: Article

References (47)

1. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, Pines M, Poult Sci 1991 70 1559 1563 1886867
2. Halofuginone: an inhibitor of collagen type I synthesis. Granot I, Halevy O, Hurwitz S, Pines M, Biochim Biophys Acta 1993 1156 107 112 8427869 (Pubitemid 23049941)
3. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M, Biochem Pharmacol 1996 52 1057 1063 10.1016/0006-2952(96)00427-3 8831725 (Pubitemid 26338264)
4. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, de-Groot N, Hochberg A, Vlodavsky I, Clin Cancer Res 1999 5 1982 1988 10473075 (Pubitemid 29399247)
5. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Elkin M, Ariel I, Miao HQ, Nagler A, Pines M, de-Groot N, Hochberg A, Vlodavsky I, Cancer Res 1999 59 4111 4118 10463616 (Pubitemid 29393586)
6. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, Dou HL, Pines M, Vlodavsky I, FASEB J 2000 14 2477 2485 10.1096/fj.00-0292com 11099465
7. Effect of halofuginone on the development of tight skin (TSK) syndrome. McGaha T, Kodera T, Phelps R, Spiera H, Pines M, Bona C, Autoimmunity 2002 35 277 282 10.1080/0891693021000001235 12482197
8. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M, J Invest Dermatol 2002 106 84 88
9. Gene expression during chemically induced liver fibrosis:effect of halofuginone on TGF- signaling. Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin O, Bruck R, Spira G, Nagler A, Kawada N, Yoshizato K, Reinhardt DP, Libermann TA, Pines M, Cell Tissue Res 2007 328 153 166 10.1007/s00441-006-0330-1 17180598 (Pubitemid 46411910)
10. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Nagler A, Genina O, Lavelin I, Ohana M, Pines M, Transplantation 1999 68 1806 1809 10.1097/00007890-199912150-00027 10609960 (Pubitemid 30004815)
11. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Pines M, Snyder D, Yarkoni S, Nagler A, Biol Blood Marrow Transplant 2003 9 417 425 10.1016/S1083-8791(03)00151-4 12869955 (Pubitemid 38351799)
12. National Cancer Institute Clinical Trials Database. http://www.cancer. gov/clinicaltrials
13. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. Koon HB, Fingleton B, Lee JY, Geyer JT, Cesarman E, Parise RA, Egorin MJ, Dezube BJ, Aboulafia D, Krown SE, J Acquir Immune Defic Syndr 2011 56 64 68 21068672
14. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni AM, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, Russo A, J Biol Chem 279 15167 15176
15. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. Roffe S, Hagai Y, Pines M, Halevy O, Exp Cell Res 2010 316 1061 1069 10.1016/j.yexcr.2010.01.003 20060825
16. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, Lefebvre RE, Unutmaz D, Mazitschek R, Waldner H, Whitman M, Keller T, Rao A, Science 2009 324 1334 1338 10.1126/science.1172638 19498172
17. Evidence that fibroblasts derive from epithelium during tissue fibrosis. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG, J Clin Invest 2002 110 341 350 12163453 (Pubitemid 34847966)
18. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R, J Biol Chem 2007 282 23337 23347 10.1074/jbc.M700194200 17562716 (Pubitemid 47311952)
19. Direct contribution of epithelium to organ fibrosis: epithelial- mesenchymal transition. Guarino M, Tosoni A, Nebuloni M, Hum Pathol 2009 40 1365 1376 10.1016/j.humpath.2009.02.020 19695676
20. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, Sherrill TP, Plieth D, Neilson EG, Blackwell TS, Lawson WE, Am J Respir Crit Care Med 2009 180 657 665 10.1164/rccm.200903-0322OC 19556518
21. Cellular and molecular mechanisms of fibrosis. Wynn TA, J Pathol 2008 214 199 210 10.1002/path.2277 18161745 (Pubitemid 351160157)
22. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D, J Biol Chem 2006 281 15090 15098 10.1074/jbc.M600030200 16489207 (Pubitemid 43855098)
23. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D, Mol Cell 2003 11 619 633 10.1016/S1097-2765(03)00105-9 12667446 (Pubitemid 36385118)
24. HepG2/C3A cells respond to cysteine deprivation by induction of the amino acid deprivation/integrated stress response pathway. Lee JI, Dominy JE Jr, Sikalidis AK, Hirschberger LL, Wang W, Stipanuk MH, Physiol Genomics 2008 33 218 229 10.1152/physiolgenomics.00263.2007 18285520 (Pubitemid 351629530)
25. Exploration of a new type of antimalarial compounds based on febrifugine. Kikuchi H, Tasaka H, Hirai S, Takaya Y, Iwabuchi Y, Ooi H, Hatakeyama S, Kim HS, Wataya Y, Oshima Y, J Med Chem 2002 49 4698 4706
26. Antimalarial activities and therapeutic properties of febrifugine analogs. Jiang S, Zeng Q, Gettayacamin M, Tungtaeng M, Wannaying S, Lim A, Hansukjariya P, Okunji CO, Zhu S, Fang D, Antimicrob Agents Chemother 2005 49 1169 1176 10.1128/AAC.49.3.1169-1176.2005 15728920 (Pubitemid 40327741)
27. Synthesis and evaluation of febrifugine analogues as potential antimalarial agents. Zhu S, Zhang Q, Gudise C, Wei L, Smith E, Zeng Y, Bioorg Med Chem Lett 2006 16 1854 1858 10.1016/j.bmcl.2006.01.009 16434194 (Pubitemid 43273263)
28. Exploration of a new type of antimalarial compounds based on febrifugine. Kikuchi H, Yamamoto K, Horoiwa S, Hirai S, Kasahara R, Hariguchi N, Matsumoto M, Oshima Y, J Med Chem 2006 49 4698 4706 10.1021/jm0601809 16854076 (Pubitemid 44162697)
29. Activating transcription factor 4. Ameri K, Harris AL, Int J Biochem Cell Biol 2008 40 14 21 10.1016/j.biocel.2007.01.020 17466566 (Pubitemid 350064577)
30. Mechanisms of Halofuginone Activity. Kamberov YG, PhD thesis Harvard University, Developmental Biology and Cell Biology Departments 2008
31. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Harding H, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D, Mol Cell 2000 6 1099 1108 10.1016/S1097-2765(00)00108-8 11106749
32. Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. Jiang HY, Wek EC, J Biol Chem 2005 280 14189 14202 10.1074/jbc.M413660200 15684420 (Pubitemid 40517321)
33. Signal integration in the endoplasmic reticulum unfolded protein response. Ron D, Walter P, Nat Rev Mol Cell Biol 2007 8 519 29 10.1038/nrm2199 17565364 (Pubitemid 46985379)
34. Identification of novel stress-induced genes downstream of CHOP. Wang XZ, Kuroda M, Sok J, Batchvarova N, Kimmel R, Chung P, Zinszner H, Ron D, EMBO J 1998 17 3619 3630 10.1093/emboj/17.13.3619 9649432 (Pubitemid 28327380)
35. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, Wang X, Ron D, Cavener DR, Wek RC, Mol Cell Biol 2004 24 1365 1377 10.1128/MCB.24.3.1365-1377.2004 14729979 (Pubitemid 38112196)
36. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H, EMBO J 2005 24 1243 1255 10.1038/sj.emboj.7600596 15775988 (Pubitemid 40516607)
37. TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway. Jousse C, Deval C, Maurin AC, Parry L, Chérasse Y, Chaveroux C, Lefloch R, Lenormand P, Bruhat A, Fafournoux P, J Biol Chem 282 21 15851 15861
38. Genomic instability, centrosome amplification, cell cycle checkpoints and Gadd45a. Hollander MC, Fornace AJ Jr, Oncogene 2002 21 40 6228 33 10.1038/sj.onc.1205774 12214253
39. Genomic instability in Gadd45a-/- cells is coupled with S-phase checkpoint defects. Hollander MC, Philburn RT, Patterson AD, Wyatt MA, Fornace AJ Jr, Cell Cycle 2005 4 704 709 10.4161/cc.4.5.1675 15846075 (Pubitemid 41353856)
40. The eukaryotic initiation factor-2 kinase pathway facilitates differential GADD45a expression in response to environmental stress. Jiang HY, Jiang L, Wek RC, J Biol Chem 2007 282 3755 3765 17170114 (Pubitemid 47084432)
41. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Lee AH, Iwakoshi NN, Glimcher LH, Mol Cell Bio 2003 23 7448 7459 10.1128/MCB.23.21.7448-7459.2003 (Pubitemid 37271447)
42. Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Zimmermann J, Erdmann D, Lalande I, Grossenbacher R, Noorani M, Fürst P, Oncogene 2000 19 2913 2920 10.1038/sj.onc.1203606 10871842 (Pubitemid 30389081)
43. AnyExpress: integrated toolkit for analysis of cross-platform gene expression data using a fast interval matching algorithm. Kim J, Patel K, Jung H, Kuo WP, Ohno-Machado L, BMC Bioinformatics 2011 12 75 10.1186/1471-2105-12-75 21410990
44. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Smyth GK, Stat Appl Genet Mol Biol 2004 3 Article 3
45. A Comparison of Normalization Methods for High Density Oligonucleotide Array Data Based on Bias and Variance. Bolstad BM, Irizarry RA, Astrand M, Speed TP, Bioinformatics 2003 19 185 193 10.1093/bioinformatics/19.2.185 12538238 (Pubitemid 36181903)
46. The positive false discovery rate: A Bayesian interpretation and the q-value. Storey JD, Annals of Statistics 2003 31 2013 2035 10.1214/aos/ 1074290335 (Pubitemid 38293903)
47. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Proc Natl Acad Sci USA 2005 102 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)